Compliance program studies should contain three arms for evaluation -- NACDS workshop.
PHARMACY COMPLIANCE PROGRAM STUDIES SHOULD ENROLL THREE ARMS of patients to assess the effectiveness of such programs in promoting compliance with drug therapy, Hoscheit Consultants' Donald Hoscheit urged at the National Association of Chain Drug Stores pharmacy conference in Boston Aug. 26. Compliance program studies should examine the behaviors of "patients who opt out...another double-blind group and then those compliant patients or those who enrolled in the program," Hoscheit said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth